TCGA data analysis revealed increased gene expression of HMGA2 in the mesenchymal GB subtype compared to the glioma CpG island methylator phenotype (G‐CIMP subtype) and up to 2% of GB patients harbor HMGA2 gene amplifications as determined by cBioPortal (Jiang et al., 2016). The gene discussed is HMGA2; the disease is central nervous system cancer.